May 21, 2021, Washington, DC—The COPD Foundation is pleased to announce that Midmark, a clinical environmental design company providing medical, dental, and veterinary solutions at the point of care, has recently joined the Foundation’s 2021 Corporate Partners Program.
The COPD Foundation began the corporate partners program in 2015 to interact with external organizations that have the shared goals of undertaking impactful initiatives relating to chronic obstructive pulmonary disease (COPD), bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
Midmark has decades-long experience in providing spirometry/pulmonary function testing devices to both primary care physicians and specialists but also considers itself an “experience company focused on design” with the goal of reducing steps or burdens to improve the point of care experience for the patient and clinician.
“Understanding the disease, those who live with that disease, and those who care for those with the disease, is essential to understand what is needed AND what is possible to improve the experience at the point of care,” explains Thomas D. Schwieterman, MD, MBA, chief medical officer and vice president of clinical affairs at Midmark. “We are designers of complete solutions and we need to fully understand all the stakeholders within COPD care to ensure each stakeholder need is addressed to provide optimal solutions.”
Midmark has a broad portfolio of solution-based products which address multiple point of care needs including patient positioning, infection prevention, medical device utilization, clinical workflow, and real-time location monitoring. The company is also active in clinical research with the aim to improve processes and look for next generation techniques and technologies.
“Our market and disease research has only solidified our depth of commitment to pulmonary care as we recognize the need for innovation in COPD diagnosis and treatment,” explains Schwieterman. “The population of patients with pulmonary diseases continues to grow and the need to improve outcomes at lower cost has never been more timely. Because COPD is a $40 billion-plus-dollar problem, the effort to improve the lives of patients and their caregivers and support health care providers is larger than any one company can do alone. It will take a team of experts, each with their own special area of contribution, to make it happen.”
Midmark joins 23 other companies in the Foundation’s corporate partners program. “We are so pleased to have this innovative company participate in our corporate partners program,” said Ruth Tal-Singer, PhD, president and chief scientific officer of the COPD Foundation. “We know our partners share our drive to constantly fuel research, find innovations, and enhance the support and care that will improve the lives of people living with COPD, bronchiectasis and NTM lung disease.”
# # #
The COPD Foundation is a not-for-profit organization that was established to improve the lives of people with COPD, bronchiectasis, and NTM lung disease through initiatives that expand services and speed innovations which will make treatment more effective and affordable. We do this through scientific research, education, advocacy, and awareness with the goal of disease prevention and progression, and ultimately a cure.